Results 51 to 60 of about 4,505 (178)
BMC Endocrine Disorders, 2018 Background Impaired insulin activity in women with polycystic ovary syndrome might differ from that seen in type 2 diabetes mellitus without polycystic ovary syndrome.
Tao Tao +3 more
doaj +1 more source
PET Imaging of Cardiac Inflammation in Viral Myocarditis Using a DPP4‐Targeted Probe
Advanced Science, Volume 13, Issue 38, 9 July 2026.This study describes a DPP4‐targeted PET probe for imaging myocardial inflammation by selectively targeting activated immune cells. Derived from the clinically approved small‐molecule inhibitor linagliptin, the probe demonstrates favorable biodistribution with specific cardiac uptake in myocarditis.
Wanhao Gao +14 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016 BackgroundCyclic guanosine monophosphate‐protein kinase G‐phosphodiesterase 5 signaling may be disturbed in heart failure (HF) with preserved ejection fraction, contributing to cardiac remodeling and dysfunction.
Jessica A. Hiemstra +18 more
doaj +1 more source
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.ICTI to evogliptin from other DPP‐4 inhibitors significantly improved glycemic control in patients with type 2 diabetes inadequately controlled on metformin‐based therapy. The treatment was well tolerated, supporting ICTI as a pragmatic optimization strategy in routine clinical practice. ABSTRACT Aims While dipeptidyl peptidase‐4 (DPP‐4) inhibitors are
Jie‐Eun Lee +14 more
wiley +1 more source
Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes
Therapeutics and Clinical Risk Management, 2010 Morali D SharmaBaylor College of Medicine, Houston, Texas, USAAbstract: Type 2 diabetes is associated with decreased incretin hormone response to an oral glucose load, and a progressive decline in postprandial glucagon-like peptide-1 (GLP-1) secretion ...
Morali D Sharma
doaj
Фармакоэкономика, 2015 Type 2 diabetes mellitus (T2DM) is one the socially important diseases in the Russian Federation (RF). Dipeptidyl peptidase-4 (DPP-4) inhibitors alogliptin, vildagliptin, linagliptin, saxagliptin and sitagliptin are registered in the RF and included in ...
Georgii Rubenovich Khachatryan +1 more
doaj +1 more source
GLP‐1 agonists and the gut microbiome: A bidirectional relationship
British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1309-1325, May 2026.Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath +2 more
wiley +1 more source
Cardiovascular Diabetology, 2018 Aims Type 2 diabetes is associated with endothelial dysfunction leading to cardiovascular disease. CD34+ endothelial Progenitor Cells (EPCs) are responsible for endothelial repair and neo-angiogenesis and can be used as a cardiovascular disease risk ...
Fiona J. Dore +11 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1265-1274, May 2026.With the increasing volume of clinical evidence derived from large‐scale Asian real‐world data (RWD) and the growing interest in its use in regulatory decision‐making, it is important to conduct benchmarking exercises that evaluate whether studies using Asian RWD can generate similar conclusions as randomized controlled trials (RCTs).
Hwa Yeon Ko +15 more
wiley +1 more source
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
Diabetes, Metabolic Syndrome and Obesity, 2010 Baptist GallwitzDept Medicine IV, Tübingen University, Otfried-Müller-Str, 10, 72076 Tübingen, GermanyAbstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes ...
Baptist Gallwitz
doaj +2 more sources